If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this Web site has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

This requires Flash to play. Click here to download.

Zolinza® [vorinostat] capsules Reactivate Expression

Home

About ZOLINZA

Efficacy

Objective Response in CTCL

Study Population

Duration of Response

Time to Progression

Visible Improvements

Safety Profile

Dosage

Reimbursement

Physician Resources

Medical Society Links

Internet Resources

Patient Education

CTCL Overview

Prescribing Information

Patient Product Information

Prescribing Information

View the Prescribing Information for ZOLINZA in PDF format.

[PDF: 176 kb, 10 pages]

To view PDF documents, you must have the Adobe Reader installed on your computer.

Connect With Merck

Sign Up for Updates

Share Information

Now Included in the 2007 NCCN Guidelines

Pivotal Data Published in the Journal of Clinical Oncology

Home | Patient Product Information | Prescribing Information

ZOLINZA is a registered trademark of Merck & Co., Inc. Copyright © 2008 Merck & Co., Inc. All rights reserved.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

20750170(10)-03/07-ZOL

For general information and other services for physicians

MerckMedicus, MerckSource, and MerckServices are trademarks of Merck & Co., Inc.